Clinical trial · Interventional
Motivational Enhancement Therapy to Improve Adherence to Aromatase Inhibitors
NCT02883361CI-TRIAL-00083373MI for AIswithdrawnPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Our team decided to conduct more preliminary work on understanding AI adherence to support the optimal development of a randomized controlled trial before proceeding with the trial.
Summary
Brief summary (as posted)
The proposed research is a randomized controlled investigation of the efficacy of motivational interviewing (MI) to improve adherence to aromatase inhibitors (AI) in a community sample of patients with poor adherence to AIs.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Medication Adherence | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Attention Control | Behavioral | — | UNRESOLVED |
| Motivational enhancement therapy | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Treatment
- description
- Receive 4 in-person motivational enhancement counseling sessions over the course of 12-months that specifically target medication adherence.
- interventionNames
- Behavioral: Motivational enhancement therapy
- type
- PLACEBO_COMPARATOR
- label
- Control
- description
- Attend 4 in-person sessions to complete questionnaires and receive educational handouts.
- interventionNames
- Behavioral: Attention Control
Primary outcomes (1)
- measure
- Medication adherence measured using medication possession ratio (MPR)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * English-speaking women, prescribed their first aromatase inhibitor medication. Been identified as non-adherent following a 6-month observation run-in period (Phase 1). Exclusion Criteria: * Unable to comply with protocols; diagnosis of cognitive impairment; severe psychopathology (e.g., schizophrenia); history of drug abuse; terminal condition with low likelihood of survival; living in a long-term care facility.
References
Publications (0)
Data not yet available
No reference posted for this study.